Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. (AMRX) amended its acquisition disclosure by adding Kashiv BioSciences, LLC’s audited consolidated statements for 2025 and 2024, unaudited interim statements through June 30, 2026, and unaudited pro forma combined information. The pro forma information is for informational purposes and does not represent actual combined results or project future results.
Kashiv’s standalone revenue was $79.96 million in 2025 versus $37.71 million in 2024; its net loss was $109.05 million, compared with $124.72 million. Kashiv used $106.3 million of cash in operations in 2025 and had an accumulated deficit of $27.71 million as of December 31, 2025. Its auditor stated that substantial doubt exists about its ability to continue as a going concern, while noting the audit opinion was not modified for that matter.
Kashiv restated its 2024 comparative statements for errors involving acquisition accounting and presentation and a lease modification; it said the errors’ impact was material to prior-period statements.
Amneal Pharmaceuticals, Inc. (AMRX) director J. Kevin Buchi reported a bona fide gift of 20,445 shares of Class A Common Stock on September 17, 2026. The shares were transferred for no consideration to a trust for which he serves as trustee. After the transfer, he held 75,077 shares directly and 113,944 shares indirectly through the trust. No Rule 10b5-1 trading plan is reported for these transactions.
Amneal Pharmaceuticals, Inc. (AMRX) director Kevin J. Buchi exercised options on September 11, 2026 to acquire 20,445 shares of Class A Common Stock at an exercise price of $14.45 per share, eliminating this option position. Following the transaction, he holds 95,522 shares directly and 93,499 shares indirectly through a trust. The exercised option was fully vested and currently exercisable, and no Rule 10b5-1 trading plan is reported.
Amneal Pharmaceuticals, Inc. (AMRX) has filed an automatic shelf registration statement on Form S-3ASR covering the resale, from time to time, of up to 28,942,098 shares of its Class A common stock by certain selling stockholders. These shares were issued as part of the equity consideration in Amneal’s acquisition of Kashiv BioSciences, LLC completed on August 10, 2026, alongside $375,000,000 in cash consideration. The cash portion was funded in part by a $350,000,000 incremental term loan, and the Kashiv sellers may receive up to an additional $350,000,000 in contingent milestone payments plus potential royalties. Amneal states it will not receive any proceeds from sales by the selling stockholders.
Amneal Pharmaceuticals, Inc. (AMRX) insider Andrew S. Boyer, an Executive Vice President, reported a bona fide gift of 80,000 shares of Class A Common Stock on September 1, 2026. The gift was made to a trust for the benefit of certain family members, and Boyer is not the trustee. Following this transfer, he reports 193,646 shares of direct holdings. No Rule 10b5-1 trading plan is reported for this transaction.
Amneal Pharmaceuticals, Inc. (AMRX) reported that Executive Vice President Andrew S. Boyer made a bona fide gift of 152,426 shares of Class A Common Stock on 2026-08-21. The shares were gifted to a trust for the benefit of certain family members, where Boyer does not serve as trustee. Following this transfer, Boyer’s reported direct holdings are 273,646 shares of Class A Common Stock.
Amneal Pharmaceuticals director John Kiely reported two transactions in Class A Common Stock on 2026-08-13. He sold 50,000 shares at a weighted average price of $17.64 per share in multiple trades within a $17.26–$17.88 range, and separately donated 10,000 shares as a charitable gift to a donor advised fund.
Amneal Pharmaceuticals, Inc. Executive Vice President Nikita Shah reported a sale of 146,403 shares of Class A Common Stock on August 12, 2026. The sale was executed at a weighted average price of $17.51 per share, with individual trade prices ranging from $17.40 to $17.67 per share. Following this transaction, Shah directly holds 253,390 shares of Amneal Class A Common Stock.
Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported selling a total of 216,613 shares of Class A Common Stock in two open-market or private transactions. On 2026-08-12 he sold 210,000 shares at $17.40 per share (weighted average, with individual trades between $17.25 and $17.67). On 2026-08-11 he sold 6,613 shares at $17.70 per share (weighted average, with individual trades between $17.65 and $17.73). The Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan, and post-transaction share holdings were not reported in this form.
BUCHI J KEVIN reported disposition transactions in this Form 4 filing.
Amneal Pharmaceuticals, Inc. director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on 2026-08-11 at a weighted average price of $17.18 per share. According to the footnote, the shares were sold in multiple trades between $17.07 and $17.31 per share. Following this activity, 93,499 shares are held indirectly by a trust and a separate holding entry shows 75,077 shares held directly.